Daiichi Sankyo opens Toronto headquarters to support Canadian oncology growth

Daiichi Sankyo has opened a permanent Canadian headquarters in Toronto, and the company supports 18 oncology clinical trials across 43 specialized sites nationwide.

Daiichi Sankyo has opened a permanent Canadian headquarters in Toronto. The company announced the move as part of a strategic push into the North American oncology market. Officials noted the investment aligns with efforts to grow Ontario's life sciences and biomedical sector. The new base is presented as a way to better navigate Canada's regulatory and healthcare landscape. Known details: - The article mentions Daiichi Sankyo Co Ltd has inaugurated a permanent Canadian headquarters in Toronto. - The company supports 18 oncology clinical trials across 43 specialized sites in Canada. - Partnerships cited include the Princess Margaret Cancer Centre and the McGill University Health Centre. - Masahiro Kato, Managing Director, Europe and Canada, said the Toronto base is a significant milestone for the company’s global expansion. - Ontario Premier Doug Ford said the investment will help create good-paying jobs and strengthen the provincial economy. - The opening ceremony included traditional Japanese cultural elements, the company said. Summary: Establishing the Toronto headquarters is described as intended to accelerate delivery of oncology therapies and to strengthen Daiichi Sankyo’s operational and research presence in Canada. Local officials framed the move as supporting job creation and Ontario’s role in life sciences development. Undetermined at this time.